2021年
Potent efficacy of chlorpromazine in acute myeloid leukemia harboring KIT-D816V mutation.
Leukemia research reports
- ,
- ,
- ,
- ,
- 巻
- 15
- 号
- 開始ページ
- 100256
- 終了ページ
- 100256
- 記述言語
- 英語
- 掲載種別
- DOI
- 10.1016/j.lrr.2021.100256
Acute myeloid leukemia (AML) is a heterogeneous disease often associated with poor prognosis. We previously showed that the localization of KIT-D816V at endolysosomes is critical to activate aberrant Akt signaling and Chlorpromazine (CPZ) perturbs the intracellular localization, leading to cell death in AML cells with KIT-D816V. We report that daily administration of CPZ, prescribed for controlling anxiety disorder in patient with AML harboring KIT-D816V, led to a dramatic reduction in AML cells. In vitro and in vivo experiments showed that CPZ inhibited the growth and survival of the patient-derived AML cells, implying potent efficacy of CPZ in AML with KIT-D816V.
- リンク情報
- ID情報
-
- DOI : 10.1016/j.lrr.2021.100256
- PubMed ID : 34194969
- PubMed Central 記事ID : PMC8233227